CA2562069A1 - Therapeutic combination for treatment of alzheimers disease - Google Patents

Therapeutic combination for treatment of alzheimers disease Download PDF

Info

Publication number
CA2562069A1
CA2562069A1 CA002562069A CA2562069A CA2562069A1 CA 2562069 A1 CA2562069 A1 CA 2562069A1 CA 002562069 A CA002562069 A CA 002562069A CA 2562069 A CA2562069 A CA 2562069A CA 2562069 A1 CA2562069 A1 CA 2562069A1
Authority
CA
Canada
Prior art keywords
active
pharmaceutically acceptable
disease
alzheimer
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002562069A
Other languages
English (en)
French (fr)
Inventor
Gregg H. Larson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2562069A1 publication Critical patent/CA2562069A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
CA002562069A 2004-04-14 2005-04-04 Therapeutic combination for treatment of alzheimers disease Abandoned CA2562069A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56214104P 2004-04-14 2004-04-14
US60/562,141 2004-04-14
PCT/IB2005/000923 WO2005099823A1 (en) 2004-04-14 2005-04-04 Therapeutic combination for treatment of alzheimers disease

Publications (1)

Publication Number Publication Date
CA2562069A1 true CA2562069A1 (en) 2005-10-27

Family

ID=34963723

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002562069A Abandoned CA2562069A1 (en) 2004-04-14 2005-04-04 Therapeutic combination for treatment of alzheimers disease

Country Status (14)

Country Link
EP (1) EP1737539A1 (enExample)
JP (1) JP2007532624A (enExample)
KR (1) KR20060133008A (enExample)
CN (1) CN1960781A (enExample)
AU (1) AU2005232447A1 (enExample)
BR (1) BRPI0509881A (enExample)
CA (1) CA2562069A1 (enExample)
IL (1) IL178120A0 (enExample)
MX (1) MXPA06011969A (enExample)
NO (1) NO20065196L (enExample)
RU (1) RU2006136361A (enExample)
TW (1) TW200533341A (enExample)
WO (1) WO2005099823A1 (enExample)
ZA (1) ZA200608239B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI432195B (zh) * 2007-10-03 2014-04-01 Kowa Co 神經細胞死亡抑制劑
SI3413870T1 (sl) * 2016-02-11 2021-12-31 Sigmathera Sas Igmezin za uporabo pri zdravljenju alzheimerjeve bolezni
MX2021015266A (es) * 2019-06-14 2022-01-18 Joshua O Atiba Composicion farmaceutica triple para infecciones proteinaceas.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020028826A1 (en) * 2000-06-15 2002-03-07 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
ES2268393T3 (es) * 2002-04-02 2007-03-16 Janssen Pharmaceutica N.V. Terapia con estatina para favorecer el mantenimiento de la funcion cognitiva.
WO2004034963A2 (en) * 2002-05-17 2004-04-29 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
JP2006512417A (ja) * 2002-12-24 2006-04-13 ニューロケム （インターナショナル） リミテッド β−アミロイド関連疾患の治療のための治療用製剤
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
US20070110715A1 (en) * 2003-03-19 2007-05-17 Ares Trading S.A. Treatment of alzheimer's disease
US20050090449A1 (en) * 2003-05-13 2005-04-28 Boehringer Ingelheim International Gmbh Novel statine derivatives for the treatment of Alzheimer's disease

Also Published As

Publication number Publication date
CN1960781A (zh) 2007-05-09
TW200533341A (en) 2005-10-16
AU2005232447A1 (en) 2005-10-27
IL178120A0 (en) 2006-12-31
BRPI0509881A (pt) 2007-10-16
ZA200608239B (en) 2008-06-25
WO2005099823A1 (en) 2005-10-27
JP2007532624A (ja) 2007-11-15
KR20060133008A (ko) 2006-12-22
EP1737539A1 (en) 2007-01-03
NO20065196L (no) 2007-01-03
RU2006136361A (ru) 2008-04-20
MXPA06011969A (es) 2006-12-15

Similar Documents

Publication Publication Date Title
JP6196225B2 (ja) 糖尿病新規発症低減用組成物
CA2403442A1 (en) Use of nateglinide alone or in combination for the treatment or prevention of diabetic complications
Jelic et al. Treatment of mild cognitive impairment: rationale, present and future strategies
JP2002529500A (ja) ＨＭＧＣｏＡレダクターゼ阻害剤を用いるアルツハイマー病の治療、予防および発症リスクの低下法
JPH07506559A (ja) 痴呆の治療における抗−リウマチ様関節炎医薬
MXPA04012149A (es) El uso de cianopirrolidinas sustituidas y prepraraciones de combinacion que las contienen para tratar hiperlipidemia y enfermedades asociadas.
RU2403039C2 (ru) Лечение биполярных расстройств и сопутствующих симптомов
Kerola et al. The complex interplay of cardiovascular system and cognition: how to predict dementia in the elderly?
CA2562069A1 (en) Therapeutic combination for treatment of alzheimers disease
Herrmann Cognitive pharmacotherapy of Alzheimer's disease and other dementias
JP2015528507A (ja) 肝性脳症を患う対象の長期生存を改善し、再入院率を低減する方法
US20060229321A1 (en) Rosuvastatin in pre demented states
Kurata et al. Cerivastatin induces carotid artery plaque stabilization independently of cholesterol lowering in patients with hypercholesterolaemia
CA3134786A1 (en) Methods for treating subjects with chronic kidney disease
CA2681185C (en) Composition useful for the prevention of type 2 diabetes and its complications in pre-diabetic patients with insulin resistance
US6358977B1 (en) Use of 4-piperidinemethanol derivatives in treatment of neurodevelopmental disorders
Fernandez et al. The use of methylphenidate in HIV patients: A clinical perspective
US20250352511A1 (en) Methods of treating focal segmental glomerulosclerosis with atrasentan
WO2003032963A2 (en) Method of reducing type 2 diabetes in high risk patients
JP4896501B2 (ja) 血中遊離脂肪酸低下作用を有する医薬組成物
JP2024505246A (ja) 神経変性認知障害を治療するための、コリンエステラーゼ阻害薬と四級アンモニウム抗ムスカリン剤との固定用量配合剤
HK40086374A (zh) 在治疗儿科患者的高脂血症和高胆固醇血症的方法中使用的洛美他派
EA047563B1 (ru) Канаглифлозин для лечения больных диабетом пациентов с хроническим заболеванием почек
Singh et al. To the Editor: Huntington_s disease (HD) is an autosomal dominant
WO2006057209A1 (ja) 血中遊離脂肪酸低下作用を有する医薬組成物

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued